Premier Research acquires regulatory firm RPI for undisclosed price

Handshake business deal executives
CRO Premier Research acquired Regulatory Professionals and will merge the regulatory firm into a new division. (Pixabay)

Global CRO Premier Research acquired Regulatory Professionals and will merge the firm into a new division focused on the regulatory process for biotech, pharma and medical device companies.

Premier Research, which is backed by the investment firm Metalmark Capital, didn’t disclose financial terms of the deal, though it announced that RPI founder and chief executive Donna Kato will head the newly created division.

RPI, based in San Francisco, was founded in 1995 and offers regulatory experience across a number of product areas and life cycles from oncology to dermatology, the company said.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

“Taking a new drug or medical device from concept to market requires a thoughtful regulatory strategy, expertly prepared documents for agency submission, and submission management in accordance with increasingly stringent requirements,” Ludo Reynders, Premier’s chief executive, said in a statement. “Joining with RPI will expand our ability to help these pioneers realize the potential of their novel therapies and life-changing innovations.”

William Blair & Company advised on the deal for Premier along with law firm Ropes & Gray. RPI was advised Edgemont Capital Partners, Lowenstein Sandler, and KPMG.

New York-based Metalmark Capital took a stake in Premier Research back in 2016, acquiring its position in the CRO from Indigo Capital, a London-based investment firm.

Suggested Articles

Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.

Charles River Labs has inked a licensing deal with drug discovery and development services provider Crown Bioscience for expanded access to the ZDSD rat model.